ACADIA Pharmaceuticals Financials - Benzinga

ACADIA Pharmaceuticals Inc

ACADNASDAQ

Trade with Public

Trade with Public

$20.68

-1.50-6.76%

가까이에: Sep 25, 5:00 PM EST

$20.69

0.01210.06%

시간외: 7:54 PM EST

PRO

변동 이유?:ACADIA Pharmaceuticals shares are trading lower after multiple analyst firm...

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

ACADIA Pharmaceuticals Financials

ACADIA Pharmaceuticals (ACAD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est

ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.

Benzinga Newsdesk

PRO
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.07 by 157.14 percent. This is a 12.5 percent increase over earnings of $0.16 per share

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
ACADIA Pharmaceuticals Affirms FY2026 Sales Guidance of $1.220B-$1.280B vs $1.247B Est

ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.220 billion-$1.280 billion vs $1.247 billion estimate.

Benzinga Newsdesk

PRO
ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.05 by 60 percent. This is a 81.82 percent decrease over earnings of $0.11 per share

Benzinga Newsdesk

PRO
ACADIA Pharmaceuticals Sees FY2026 Sales $1.220B-$1.280B vs $1.203B Est

ACADIA Pharmaceuticals (NASDAQ:ACAD) sees FY2026 sales of $1.220 billion-$1.280 billion vs $1.203 billion analyst estimate.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved